

Gynaecologic Cancer

A Handbook for Students and
Practitioners

Rushdan Noor
Eng Hseon Tay
Jeffrey Low



Gynaecologic Cancer

Gynaecologic Cancer

A Handbook for Students and
Practitioners

Rushdan Noor
Eng Hseon Tay
Jeffrey Low

Published by

Pan Stanford Publishing Pte. Ltd.
Penthouse Level, Suntec Tower 3
8 Temasek Boulevard
Singapore 038988

Email: editorial@panstanford.com
Web: www.panstanford.com

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Gynaecologic Cancer: A Handbook for Students and Practitioners

Copyright © 2014 Pan Stanford Publishing Pte. Ltd.

All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the publisher.

For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.

ISBN 978-981-4463-06-5 (Hardcover)

ISBN 978-981-4463-07-2 (eBook)

Printed in the USA

Contents

Preface

xxxv

1. World Cancer Statistics and Burden of Gynaecological Cancer	1
Introduction	2
World Cancer Burden and Contributing Factors	4
Breast Cancer	7
Cervical Cancer	7
Uterine Cancer	8
Ovarian Cancer	9
Other Gynaecological Cancers	9
Glossary of Terms	9
2. Genes and Carcinogenesis	13
Basic Structure of DNA	13
Gene	13
Genes and Carcinogenesis	15
Phases of Carcinogenesis	16
Initiation Phase	16
Promotion Phase	16
Progression Phase	17
Stem Cell and Cancer	17
Chronic Inflammation and Cancer	17
Infection and Cancer	18
Genetic Alterations in Cancer	18
Human Genome and Cancer	18
Types of Genetic Alteration in Cancer	19
Germ Line Mutations	19
Somatic Mutations	19

Genetic Alterations in Cancer	19
Pathways of Carcinogenesis in Familial and Sporadic Gynaecologic Cancers	20
Specific Genetic Alterations Responsible in Carcinogenesis	20
Genes and Malignant Transformation	21
Proto-Oncogenes	21
Tumour Suppressor Genes	21
Oncogenes	22
Other Genes Responsible in Carcinogenesis	23
Additional Facts about Oncogenes and Tumour Suppressor Genes	24
Proposed Mechanism How Oncogenes Can Transform Normal Cells to Malignant Cells	25
Cancer Spread (Invasion and Metastases)	26
Apoptosis	26
Telomerase and Cancer	27
Genetic Studies in Gynaecologic Malignancies	27
Ovarian Cancer	27
Cervical Cancer	28
Vulvar Cancer	29
Endometrial Cancer	29
Clinical Implications of Molecular Genetics in Gynaecological Cancer	30
Proteomics and Cancer	31
3. Cancer of Vulva	35
Introduction to Anatomy of Vulva	36
Vulva	36
Blood Supply and Innervation of the Vulva	38
Lymphatic Supply of the Vulva	39
Premalignant Vulvar Lesions	41
Lichen Sclerosus	41
Treatment for Lichen Sclerosus	42
Extramammary Paget's Disease of Vulva	42

Treatment for Non-mammary Paget's Disease	44
Vulva Intraepithelial Neoplasm	44
Usual Vulvar Intraepithelial Neoplasia	44
Treatment of Vulva Intraepithelial Neoplasm	45
Surgical Treatment for Vulva Intraepithelial Neoplasm	46
Medical Treatment for Vulva Intraepithelial Neoplasm	46
Photodynamic Therapy for Cervical Intraepithelial Neoplasia	46
Differentiated Vulva Intraepithelial Neoplasm	47
Vulvar Cancer	48
Presentations and Diagnosis	49
Patterns of Spread in Vulvar Cancer	49
Staging of Vulvar Cancer	50
Prognostic Factors in Squamous Cell Carcinoma of Vulvar	52
Management of Squamous Cell Carcinoma of Vulva	53
Surgical Treatment	53
Surgery for Early Stage	54
Surgical Tips during Vulvectomy and Inguino-Femoral Lymphadenectomy	55
Lymphatic Mapping and Sentinel Node Biopsy	56
Lymphatic Mapping and Sentinel Node Biopsy in Vulva Cancer	56
Method of Sentinel Node Detection	58
Radiotherapy in Early-Stage Vulvar Cancer	59
Objectives of Radiotherapy in Vulvar Cancer	60
Treatment for Advanced-Stage Carcinoma of Vulva	62
Treatment for Locally Advanced Disease	62
Treatment for Metastatic and Recurrent Disease	63
Post-Operative Care for Vulvectomy	65
General measures	65
Urinary catheter	65
Drain	65
Perineal care	65

Bowel	66
Mobilization	66
Complications of Surgery in Vulva Cancer	66
Follow-Up of Patients with Vulvar Cancer	67
Prognosis	67
Other Carcinoma of Vulvar Carcinoma	67
Verrucous carcinoma	67
Basal cell carcinoma	68
Merkel-cell tumours	68
Transitional cell carcinoma	69
Carcinoma of Bartholin's gland	69
Other Malignant Tumour of Vulva	69
Malignant melanoma of the vulva	69
Vulvar sarcoma	71
Other vulvar malignancies	72
Appendix	72
4. Carcinoma of Vagina	81
Basic Anatomy of the Vagina	82
Carcinoma of Vagina	83
Aetiology of Vaginal Cancer	84
Histological Types of Primary Vaginal Cancer	84
Adenocarcinoma of the Vagina	84
Clear Cell Adenocarcinoma of the Vagina	85
Vaginal Intraepithelial Neoplasia	86
Treatment of Vaginal Intraepithelial Neoplasm	87
Clinical Presentation of Vaginal Carcinoma	89
Staging of Vaginal Carcinoma	89
Management of Vaginal Cancer	90
Surgery in Stage 1 Disease	90
Treatment of Stage 2–4 Vaginal Cancer	90
Radiation Therapy in Vaginal Cancer (Stage by Stage)	91
Radiation Therapy for Stage 1	91
Radiation Therapy for Stage 2A	92
Radiation Therapy for Stage 2B, Stage 3 and Stage 4A	92

Survival	92
Vaginal Melanoma	92
Small Cell Carcinoma of Vagina	93
Clear Cell Adenocarcinoma of Vagina	93
Vaginal Recurrences	94
Other Vaginal Cancers	94
5. Screening for Cervical Cancer	97
Basics in Cancer Screening	98
How to Calculate Sensitivity and Specificity	98
Cervical Cancer Prevention	99
Screening of Cervical Cancer	99
Screening Population	101
Cytologic Screening for Cervical Cancer and Its Precursors	102
Liquid-Based Cytology	104
Technologies Related to Liquid-Based Cytology	105
ThinPrep Pap Test	105
AutoCyte PREP	106
PapNet	106
AutoPap	106
ThinPrep Imaging System	106
Bethesda System of Reporting Pap Smear Results	107
Terminology of Cytologic Reports	107
Bethesda 2001 Reporting System	107
Non-Cytologic Method of Screening	108
Visual Inspection	109
Steps to Perform VIA/VILI	110
HPV Testing	111
Role of HPV Testing	111
Triage of Women with Equivocal Cytology	112
Follow-Up of Patient after Treatment for CIN 2–3	113
HPV Testing in Screening and Treat Approach	113
HPV Testing as Primary Screening Test for Cervical Cancer	114

Optoelectronic Device for Cervical Cancer Screening	120
New Technologies in Cervical Cancer Screening	121
6. Human Papillomavirus and HPV Vaccination	129
HPV Infection in Lower Genital Tracts	130
Human Papillomavirus	130
Transmission of HPV	134
Burden of HPV Infections	135
Pathogenesis of HPV Infections	138
HPV Infection in Man	140
Methods of HPV Detection	142
HPV Vaccine	143
HPV Vaccine Trial	149
Quadrivalent Vaccine Trials	149
Bivalent HPV Vaccine Trials	153
Safety of Quadrivalent HPV Vaccine	156
Safety of Bivalent Vaccine	157
WHO Global Advisory Committee (GAC) Statement on the Update of HPV Vaccine Safety by 2013	158
HPV Vaccination in Males	159
HPV Vaccine: Policy and Administration Guidelines	160
Future Direction	163
7. Management of Preinvasive Disease of the Cervix	171
Introduction	172
Management of Abnormal PAP Smear	173
Colposcopy	173
Indications for Colposcopy	176
Objectives of Colposcopy	176
HPV Testing and Colposcopic Referral	178
Management of Cervical Intraepithelial Neoplasm	179
Loop Electrosurgical Excision Procedure	183
Counselling after LEEP/LLETZ	184
Cryotherapy	186
Post-Cryotherapy Care	187

Side Effects of Cryotherapy (Very Rare)	188
Laser Treatment for Preinvasive Lesions of Cervix	188
Types of Transformation Zone	189
Management of Abnormal PAP Smear, CIN and Colposcopy during Pregnancy	190
Cervical Adenocarcinoma in situ	191
HPV Testing and Other Markers in the Follow-Up after Treatment for CIN	192
8. Cancer of Cervix	197
Anatomy	198
Cancer of Cervix	200
Epidemiology	200
Aetiology of Cervical Cancer	200
HPV and Cervical Carcinogenesis	202
Types of HPV in Cervical Cancer	204
Risk Factors for Cervical Cancer	204
Histopathological Subtypes of Cervical Cancer	206
Natural History and Pattern of Spread	207
Presentations	208
Diagnosis	209
Staging Carcinoma of Cervix	209
Prognostic Factors	212
Management of Cervical Cancer	214
Treatment for Early-Stage Cervical Cancer	215
Surgical Treatment for Stage 1A1	215
Surgical Treatment for Stage 1A2	216
Surgical Treatment for Stage 1B1 and Stage 2A1 Cervical Cancer	217
Treatment for Stage 1B2 and 2A2	218
Treatment for Stage 2B-4	220
Role of Adjuvant Radiotherapy or Chemoradiation after Surgery	220
Radical Hysterectomy for Cervical Cancer	222
Nerve-Preserving Radical Hysterectomy	226

Complications of Radical Hysterectomy	227
Fertility-Preserving Surgery in Cervical Cancer	228
Radical Trachelectomy	228
Neoadjuvant Chemotherapy Followed by Fertility-Preserving Surgery	230
Cone Biopsy or Simple Trachelectomy	230
Radiotherapy in Cervical Cancer	230
Concurrent Chemoradiation in Cervical Cancer	234
Chemotherapy in Cervical Cancer	238
Chemotherapy for Metastatic and Recurrent Cervical Cancer	239
Neoadjuvant Chemotherapy in Cervical Cancer	242
Treatment for Non-Squamous Cell Carcinoma of Cervix	245
Recurrent Carcinoma of Cervix	247
Recurrence after Definitive Irradiation	248
Recurrence after Previous Surgery	250
Appendix	250
9. Carcinoma of Endometrium	263
Anatomy of the Uterus	264
Epithelial Uterine Cancer	266
Epidemiology	266
Type of Endometrial Cancer	267
Risk Factors for Endometrial Cancer	270
Pre-Malignant Lesions of Endometrium and Pathogenesis of Endometrial Cancer	272
Prevention of Endometrial Cancer	277
Presentation and Diagnosis	278
Investigations and Staging	280
FIGO Staging of Endometrial Cancer	282
Treatment for Pre-Malignant Lesions of Endometrium	283
Treatment for Endometrial Carcinoma	287
Surgery	287
Radiotherapy	292
Combination of Radiotherapy and Chemotherapy	297

Systemic Treatment for Endometrial Cancer	298
Uterine Papillary Serous Carcinoma	300
Epithelial Endometrial Cancer: Prognosis and Recurrent Disease	302
Targeted Therapy in Endometrial Cancer	304
10. Uterine Sarcoma	315
Introduction	316
Presentation and Pre-Operative Diagnosis of Uterine Sarcoma	317
Staging for Uterine Sarcoma	318
Leiomyosarcoma	319
Treatment for Uterine Leiomyosarcoma	321
Endometrial Stromal Sarcoma	324
Treatment for Endometrial Stromal Sarcoma	326
Poorly Differentiated and Undifferentiated Uterine Sarcoma	327
Adenosarcoma	327
Uterine Carcinosarcoma	328
Treatment of Uterine Carcinosarcoma	330
11. Cancer of Fallopian Tube	339
Introduction	340
Anatomy	340
Clinical Presentation	341
Diagnostic Work-Up	341
Pathology	342
Four Criteria for Pathologic Diagnosis of Primary Fallopian Tube Carcinoma	344
Pre-Invasive Carcinoma of Fallopian Tube	344
General Management	344
Surgery	344
Chemotherapy in Fallopian Tube Carcinoma	345
Adjuvant Radiation Therapy	346

12. Cancer of Ovary (Epithelial Ovarian Cancer)	349
Introduction	350
Anatomy of Ovary	350
Epidemiology	351
Incidence and Mortality	351
Aetiology	352
Reproductive Factors	352
Genetic Factors	353
Environmental Factors	354
Hereditary Ovarian Cancer Syndromes	354
Site-Specific Ovarian Cancer	355
Hereditary Breast-Ovarian Cancer	355
Hereditary Non-Polyposis Colorectal Syndrome	355
Other Hereditary Syndromes Predisposing to Ovarian Cancer	356
Somatic Mutation in Sporadic Ovarian Cancer	356
Mechanisms of Ovarian Carcinogenesis	356
Prevention of Ovarian Cancer	357
Hereditary Ovarian Cancer and Genetic Testing	359
Screening for Ovarian Cancer	361
Pelvic Examination	361
Ultrasound Scans	361
Tumour Markers	362
CA125	362
Additional Markers	362
Multi-Modal Screening Tests	363
Histologic Classification of Ovarian Neoplasm (General)	365
Serous Tumour of the Ovary	365
Mucinous Tumour of the Ovary	368
Endometrioid Tumours	368
Clear Cell Tumours	369
Transitional Cell Tumour (Brenner Tumour)	369
Undifferentiated Carcinoma of Ovary	370
Hypercalcaemic Type	370

Pulmonary Type	371
Natural History and Patterns of Spread in Epithelial Ovarian Cancer	371
Diagnosis and Clinical Evaluation	372
Biomarkers and Risk Assessment	373
Risk of Malignancy Index	373
OVA1 Test	374
Risk of Ovarian Malignancy Algorithm	375
New Tumour Markers in Ovarian Cancer	375
Staging Carcinoma of Ovary	376
Prognostic Factors for Epithelial Ovarian Cancer	378
CA125 as Prognostic Factor in Epithelial Ovarian Cancer	379
Other Prognostic Factors for Ovarian Cancer	379
Ploidy Analysis	379
Image Cytometry	379
Genetic and Biologic Factors	380
Borderline Tumour (Tumour of Low Malignant Potential)	380
Management of Tumours with Low Malignant Potential	382
Early-Stage Disease	382
Stage 3 and 4 Borderline Tumour	382
Treatment for Invasive Epithelial Ovarian Cancer	382
Treatment for Early Stage of Epithelial Ovarian Cancer	382
Chemotherapy in Early Stage (Stages 1 and 2)	383
Management of Patients with Advanced Epithelial Ovarian Cancer	384
Cytoreductive Surgery	384
Post-Operative Chemotherapy (First Line) in Ovarian Cancer	388
Chemotherapeutic Drugs as First Line Regimen in Ovarian Cancer (Post-Operative Adjuvant Treatment)	388
Platinum Compounds	388
Doxorubicin and Platinum Combination	389
Taxanes	390

Dose of Platinum and Paclitaxel	391
Addition of Targeted Agents and Novel Agents to Platinum/Taxanes Regimen (Triplets)	393
Trials on Alternative Regimen as First Line Chemotherapy in Ovarian Cancer	394
Intraperitoneal Chemotherapy	396
Hyperthermia Intraperitoneal Chemotherapy	398
Open Abdominal Technique	398
Close Abdominal Technique	398
Maintenance Therapy	399
Neoadjuvant Chemotherapy	399
Recurrent Ovarian Cancer	402
Treatment of Platinum-Sensitive Patients	403
Secondary Cytoreduction for Platinum-Sensitive Patients	404
Chemotherapy for Platinum-Sensitive Patients	405
Options of chemotherapy for platinum-sensitive tumour	405
Treatment for Platinum-Resistant and Refractory Epithelial Ovarian Cancer	407
Chemotherapy for Platinum-Resistant and Refractory Ovarian Cancer	408
Topotecan	408
Gemcitabine	408
Pegylated Liposomal Doxorubicin	408
Oral Etoposide	409
Paclitaxel and Docetaxel	409
Second Look Laparotomy/Laparoscopy	410
Techniques of Second Look Laparotomy	410
Novel Anticancer Agents for Platinum-Resistant/ Refractory Epithelial Ovarian Cancer	411
Novel Cytotoxic Agents	412
Epothilones	412
Canfosfamide (Telcyta TLK286)	412
Yondelis (ET-743)	413
Phenoxodiol	413

Targeted Agents	414
Monoclonal Antibody (Large Molecule Inhibitors)	414
Bevacizumab (Avastin)	415
Cetuximab (Erbix)	415
Trastuzumab (Herceptin)	416
Small-Molecule Inhibitors	416
Imatinib Mesylate (Gleevec)	416
Gefitinib (Iressa)	416
Erlotinib (Tarceva, OS1774)	417
Sorafenib (Nexavar, BAY 43-0006)	417
Sunitinib (Sutent)	417
Pazopanib (Votrient)	417
Cediranib	418
Other Targeted Therapies	418
Special Consideration in Ovarian Cancer Management	419
Radiation Therapy in Ovarian Cancer	419
Radiation Therapy after Chemotherapy in Advanced Disease	421
Radiation as Palliative Treatment for Ovarian Cancer	421
Palliative Surgery for Ovarian Cancer	422
Hormonal Therapy and Receptors in Ovarian Carcinoma	422
Biologic Therapy for Ovarian Cancer	423
Reversal of Drug Resistance	424
Gene Therapy	425
13. Ovarian Germ Cell Tumours	437
Introduction	438
Epidemiology	438
Clinical Features	438
Classification of Ovarian Germ Cell Tumours	439
Tumour Markers in Malignant Ovarian Germ Cell Tumours	440
Dysgerminoma	441
Yolk Sac Tumour (Endodermal Sinus Tumour)	443

Mature Teratoma	444
Immature Teratomas	446
Growing Teratoma Syndrome	448
Embryonal Carcinoma and Choriocarcinoma	449
Mixed Germ Cell Tumour	449
Management	450
Surgery and Adjuvant Chemotherapy in Malignant Germ Cell Tumours	450
Primary Surgery	451
Cytoreductive Surgery	452
Chemotherapy in Advanced Disease	452
Chemotherapy for Recurrent Disease	453
Late Effect of Therapy	454
14. Ovarian Sex Cord-Stromal Tumours	457
Introduction	458
Classification of Sex Cord-Stromal Tumours	458
Granulosa-Stromal Cells Tumour	459
Granulosa Cell Tumours	459
Adult-Type Granulosa Cell Tumour	461
Juvenile-Type Granulosa Cell Tumour	462
Tumour in the Thecoma-Fibroma Group	463
Thecoma (Theca Cell Tumour)	463
Fibroma	464
Sclerosing Stromal Tumour	465
Signet-Ring Stromal Tumour	465
Sertoli-Stromal Cell Tumours	466
Sertoli Cell Tumour	466
Sertoli-Leydig Cell Tumours	466
Sertoli-Leydig Cell Tumour with Heterologous Elements	467
Retiform Variants	467
Sex Cord-Stromal Tumours of Mixed or Unclassified Cell Types	468

Sex Cord Tumour with Annular Tubules	468
Gynandroblastoma	468
Steroid Cell Tumours	469
Stromal Luteoma	469
Leydig Cell Tumours	470
Steroid Cell Tumours, Not Otherwise Specified	470
Treatment of Ovarian Sex Cord-Stromal Tumours	471
Operative Management	471
Post-Operative Management	472
15. Gestational Trophoblastic Diseases	475
Introduction	476
Epidemiology	476
Risk Factors for Gestational Trophoblastic Disease	476
Classification of Gestational Trophoblastic Disease	477
Pathogenesis of Gestational Trophoblastic Disease	478
Hydatidiform Mole	478
Presentations of Hydatidiform Mole	480
Presentations of Complete Hydatidiform Mole	481
Presentations of Partial Mole	482
Diagnosis of Hydatidiform Mole	482
Human Chorionic Gonadotropin in Gestational Trophoblastic Disease	483
Management of Hydatidiform Mole	484
Natural History of Molar Pregnancy and Prognostic Factors	486
Gestational Trophoblastic Neoplasm	486
Metastatic Gestational Trophoblastic Neoplasm	489
Staging and Prognostic Scoring in Gestational Trophoblastic Neoplasm	490
Treatment of Low-Risk Gestational Trophoblastic Neoplasm	492
Treatment for High-Risk and Metastatic Gestational Trophoblastic Neoplasm	494
Treatment of Placental Site Trophoblastic Tumour	495

Post Chemotherapy Follow-Up	496
Chemotherapy Regimen for Gestational Trophoblastic Neoplasm	497
16. Breast Cancer for Gynaecologic Oncologist	503
Basic Anatomy of the Breast	504
Introduction to Breast Cancer	505
Aetiology of Breast Cancer	506
Breast Cancer Risks	506
Reproductive Factors/Endogenous Hormones	506
Pregnancy and Lactation	507
Family History and Other Gynaecological Cancer	507
Oral Contraceptive Pills	508
Hormone Replacement Therapy	508
Personal History	509
Risk Assessment of Breast Cancer	509
Breast Cancer and Genetic Factors	510
Screening for Breast Cancer	512
Breast Self-Examination and Clinical Breast Examination	512
Mammography	512
Reporting of Mammogram	514
Magnetic Resonance Imaging	514
Evaluation of Patients with Breast Cyst and Solid Breast Lump	515
Breast Cyst	515
Solid Breast Lump	516
Evaluation of Non-Palpable Mammographic Abnormalities	516
Ductal Carcinoma in situ	517
Lobular Carcinoma in situ	518
Mammary Paget Disease	518
Invasive Carcinoma of Breast	518
Prognostic Factors of Invasive Carcinoma of Breast	519
Presentation	520

Evaluation of Patients with Breast Cancer	521
Staging of Breast Cancer	522
Treatment for Breast Cancer	523
Surgical Treatment	523
Types of Surgical Treatment for Breast Cancer	524
Radiotherapy	525
Systemic Therapy	526
Chemotherapy for Breast Cancer	527
Hormonal Therapy for Breast Cancer	527
Targeted Therapy for Breast Cancer	528
Human Epidermal Growth Factor Receptor (HER 2)	
Inhibitor	528
Lapatinib	530
Anti-Angiogenesis	530
Locally Advanced Breast Cancer	530
Prevention of Breast Cancer	531
Current Recommendations of Chemoprevention	532
17. Gynaecologic Cancer during Pregnancy	539
Introduction	540
Radiation Exposure during Pregnancy	540
Radiotherapy during Pregnancy	543
Chemotherapy and Targeted Therapy during Pregnancy	543
Management of Gynaecological Cancer during Pregnancy	545
Breast Cancer	546
Cervical Cancer	546
Ovarian Cancer	549
Vulvar Cancer	551
Carcinoma of Endometrium	551
Choriocarcinoma	551
18. Tumour Markers in Gynaecologic Cancers	555
Introduction	556
Tumour Markers in Ovarian and Fallopian Tube Cancer	557
Cancer Antigen 125	557

Serum Biomarkers in Screening of Epithelial Ovarian Cancer	559
Serum Biomarkers in the Evaluation of Women with Pelvic Masses	560
Biomarkers for Monitoring the Disease Status in Epithelial Ovarian Cancer	562
Carcinoembryonic Antigen	562
Alpha-Fetoprotein	562
Human Chorionic Gonadotrophin	563
Lysophosphatidic Acid	563
Inhibin and Activins	563
New Tumour Markers in Ovarian Cancer	563
Tumour Markers in Cervical Cancer	565
Squamous Cell Carcinoma Antigen	565
CA125 in Cervical Cancer	566
CYFRA 211-1	566
Other Markers in Cervical Cancer	567
Tumour Markers in Endometrial Cancer	567
19. Diagnostic Imaging in Gynaecologic Oncology	571
Introduction	572
Imaging Study: Technique, Description and Normal Anatomy	572
Ultrasound	572
Ultrasound Features of Normal Uterus and Ovary	573
Computed Tomography	573
Magnetic Resonance Imaging	574
Advantages of Magnetic Resonance Imaging	575
Disadvantages of MRI	576
Imaging in Cervical Carcinoma	576
CT Scan and Cervical Cancer	576
Magnetic Resonance Imaging in Cervical Cancer	577
Imaging in Endometrial Carcinoma	578
Ultrasound Scan in Endometrial Carcinoma	578

CT Scan in Endometrial Carcinoma	578
Magnetic Resonance in Endometrial Carcinoma	579
Imaging in Gestational Trophoblastic Disease	580
Ultrasound in Gestational Trophoblastic Disease	580
CT Scan in Gestational Trophoblastic Disease	580
Magnetic Resonance Imaging in GTD	581
Imaging in Carcinoma of Ovary	581
Ultrasound Scan and Doppler in Ovarian Carcinoma	581
CT Scan in Ovarian Carcinoma	581
MRI in Ovarian Carcinoma	583
Imaging in Vulvar Cancer	583
Ultrasound Scan in Vulvar Cancer	583
CT Scan in Vulvar Cancer	584
MRI in Vulvar Cancer	584
Lymphoscintigraphy and Sentinel Node Detection in Vulvar Cancer	584
Positron Emission Tomography in Gynaecologic Malignancies	585
F-FDG Pet Scan in Cervical Cancer	586
F-FDG Pet Scan in Endometrial Cancer	586
F-FDG PET Scan in Ovarian Cancer	587
20. Peri-Operative Care for Gynaecologic Cancer Patients	589
Introduction	590
Peri-Operative Morbidity and Mortality Risk Prediction	590
Peri-Operative Care to Optimize High-Risk Surgical Patients Undergoing Gynaecological Cancer Surgery	592
Informed Consent and Counselling	592
Peri-Operative Care in Gynaecological Cancer Patients	
History and Physical Examination	593
Pre-Operative Investigations	593
Optimization of Co-Morbid Illnesses	593
Endocrine-Related Conditions	593
Cardiac Disease	594

Respiratory Disease	595
Renal Disease	595
Haematological Disorders	596
Peri-Operative Thromboprophylaxis	596
Peri-Operative Nutritional Support for Cancer Patients	599
Peri-Operative Fluid and Electrolyte Management	601
Bowel Preparation	603
Pain Management	605
21. Basic Anatomy and Principles of Surgery in Gynaecologic Oncology	609
Basic Anatomy of the Pelvis	610
Pelvic Ligaments	611
Pelvic Spaces	611
Internal Iliac Artery	613
Ureter	613
Pelvic Lymph Nodes	615
Pelvic Nerve	617
Introduction to Anatomy of Vulva	618
Vulva	618
Blood Supply and Innervation of the Vulva	621
Lymphatic Supply of the Vulva	621
Peritoneal Cavity	623
Omentum	624
Blood Supply to the Bowel	625
Bowel Injury and Basic Bowel Surgery	625
Small and Large Bowel Resection and Anastomosis	627
Urinary Tract Injuries and Repair	628
Basic Surgical Techniques in Gynaecological Surgery	629
Fasting and Bowel Preparation	629
Skin Preparation	630
Skin Incision	630
Surgical Drain	632
Basic Principles in Gynaecologic Oncology Surgery	633

22. Basic Principles of Radiotherapy	637
Introduction	638
Biologic Effects of Radiation	640
Radiocurability and Radiosensitivity	640
Effects of Irradiation on Foetus	642
General Concepts of Clinical Radiation Therapy	642
Effects of Irradiation on Abdominal and Pelvic Normal Tissues	645
Potential Sites and Nature of Radiation Injuries in Gynaecologic Cancer Patients	646
Combination of Irradiation with Other Therapeutic Modalities	647
Processes of Radiation Therapy	648
Current Developments in Radiotherapy	650
Intensified Modulated Radiation Therapy	650
Image-Guided Radiation Therapy	651
Stereotactic Radiosurgery	651
Other Types and Methods of Radiotherapy	652
Electron Radiation Therapy	652
Proton Beams	652
Neutron Beam Therapy	652
Intra-Operative Radiation Therapy	652
Hyperthermia and Radiotherapy	653
Basic Equipment for Radiotherapy in Gynaecology	
Oncology	653
Shielding for EBRT	656
23. Basic Principles of Chemotherapy	659
Introduction	660
Basic Cell Cycles	660
Stages of Cell Cycle	660
Interphase	661
Mitosis	661
Gompertzian Growth Concepts	662
Generation and Doubling Time	662

Types of Anti-Neoplastic Agents Related to Cell Cycle	663
Drug Resistance	665
Possible Mechanisms Associated with Resistance to Some Commonly Used Anti-Cancer Drugs	667
Categories of Chemotherapeutic Drugs Used in the Treatment of Gynaecological Cancer	667
Alkylating Agents	667
Platinum	668
Anti-Tumour Antibiotics and Anthracyclines	668
Anti-Metabolites	669
Vinca Alkaloids	670
Topoisomerase Inhibitors	670
Taxanes	671
Chemotherapy and Toxicity	672
Haematologic Toxicity	672
Gastrointestinal Toxicity	672
Skin Reactions	672
Cardiac Toxicity	673
Genitourinary Toxicity	673
Neurologic Toxicity	673
Gonadal Dysfunction	673
Carcinogenicity	673
Basic Practical Chemotherapy	674
Evaluation of New Agents	674
Important Considerations before Using Chemotherapeutic Drugs	674
Performance Status	675
Types of Chemotherapy	676
Definitions of Response (WHO Guidelines)	676
Response Evaluation Criteria in Solid Tumours	677
Calculation of Dosage	678
Important Tips in Chemotherapy	679
Management of Recurrent Disease	679
Principle of combination chemotherapy	679

Supportive and Preventive Care for Chemotherapy-Induced Myelosuppression	679
GM-CSF and G-CSF	680
Erythropoietin	681
Overcoming Nausea and Vomiting during Chemotherapy	681
General Principles	683
Type of Chemotherapy-Induced Nausea and Vomiting	683
Dose Modification Guidelines	684
General Principle of Dose Modification	685
24. Modulating Agents, Biologic Response Modifiers and Targeted Therapy in Gynaecological Cancer	687
Modulating Agents in Cancer	688
Modulating Agents	688
Folinic Acid	688
Dexrazoxane (Zinecard)	689
Thiol-Based Chemoprotectors	689
Glutathione	689
Amifostine (Ethyol)	690
Sodium Thiosulphate	690
Mesna	691
Glutamine	691
Fibroblast Growth Factors	692
Recombinant Human Erythropoietin	692
Granulocyte-Colony Stimulating Factor and Granulocyte Macrophage-Colony Stimulating Factor	693
Biologic Response Modifiers	694
Inflammation and Tumour	694
Cytokines and Tumour Growth	695
Chemokines and Tumour Growth	695
Cyclooxygenase and Tumour	696
Biologic Response Modifiers in Current Clinical Practices	697
Interferons	697

Interleukins (IL-1, 2, 3, 4)	697
Tumour Necrosis Factor	698
Retinoids	698
Modulators of Resistance to Chemotherapy	698
Modulators of P-Glycoprotein	699

25. Immunotherapy and Hormonal Therapy in

Gynaecological Cancer 703

Tumour Immunology and Immunotherapy	704
Principles of Immunotherapy	707
Immunotherapeutic Approaches	708
Active Immunotherapy	708
Passive Immunotherapy	708
Potential Approaches for Cancer Vaccination Strategy	709
Anti-Idiotypic Antibody-Based Vaccine (Using Monoclonal Antibody Technology)	709
Dendritic Cell-Based Vaccines	709
DNA and RNA Vaccines	709
Viral Vector-Based Vaccines	709
Particle-Based Vaccines	710
Hormonal Interactions and Hormonal Therapy in Cancer	710
Hormones	710
Types of Hormones	710
Receptors	710
Hormonal Interactions in Breast Cancer	711
Endogenous Sex Steroid and Breast Cancer	711
Exogenous Sex Steroid and Breast Cancer	711
Oestrogen and Anti-Oestrogen in Breast Cancer	712
Progestogen and Breast Cancer	713
Hormonal Therapy in Endometrial Adenocarcinoma	713
General	713
Progestogen Therapy in Endometrial Neoplasia	714
Endometrial Hyperplasia	714
Endometrial Carcinomas	714

Other Potential Hormonal Treatment for Endometrial Carcinoma	714
Steroid Receptors and Predictive Tests for Endometrial Cancer	715
Endometrial Stromal Sarcoma	715
Hormonal Therapy and Receptors in Ovarian Carcinoma	716
HRT in Patients Treated for Gynae Malignancy	716
OCP and Prevention of Ovarian and Endometrial Cancer	717
26. Management of Long-Term Side Effects of Gynaecologic Cancer Treatment	721
Introduction	722
Side Effects of Chemotherapy	722
Mucositis	722
Alopecia	722
Myelodysplastic Syndrome and Acute Non-Lymphocytic Leukaemia	722
Cardiac Toxicity	723
Pulmonary Toxicity	723
Neurotoxicity	724
Renal Insufficiency	724
Infertility and Mutagenic Potential	725
Neutropenic Sepsis	725
Central Nervous System Adverse Effects Induced by Chemotherapy	726
Side Effects of Radiation Therapy	727
Predisposing Factors to Radiation-Related Complications	728
Host Factors	728
Disease-Related Predisposing Factors	728
Treatment-Related Predisposing Factors	728
Gastrointestinal Radiation Toxicity	728
Pathogenesis of Acute and Late Radiation Toxicity	730
Urinary Tract Radiation Injury	730
Ureteric Radiation Injury	730

Bladder Radiation Injuries	731
Sexual Function	731
Secondary Malignancies	731
Surgical Complications in Gynaecologic Surgery	732
Urinary Tract Injuries	732
Intestinal Injuries	733
Intra-operative Injuries	733
Post-operative Injuries	733
Appendix	734
Common Toxicity Criteria (Simplified CTC Ver. 3.0)	734
Non-Haematological Toxicities	737
27. Nutritional Support for Gynaecologic cancer Patients	741
Nutritional Assessment	743
Methods of Nutritional Assessment	743
Anthropometric and Biochemical Markers	743
Subjective Global Assessment	744
Aetiology of Malnutrition	744
Decreased Food Intake	744
Malabsorption	744
Metabolic Derangement	745
Nutritional Therapies	745
Goals of Nutritional Therapy	745
Enteral Nutrition	746
Types of Administration of Enteral Feeding	747
Bolus Feeding	747
Continuous Infusion	747
Efficacy of Enteral Feeding	747
Indications for Enteral Nutrition in Cancer Patients	748
Complications of Enteral Nutrition	748
Home Enteral Nutrition	748
Oral Dietary Therapy	749
Pharmacologic Agents	750
Appetite Stimulants	750

Cytokine Inhibitors	750
Other Agents and Modality to Increase Weight	750
Total Parenteral Nutrition	751
Indications of Total Parenteral Nutrition	751
Roles of Total Parenteral Nutrition in Cancer Patients	752
Indications for TPN in Hospitalized Patients with Gynaecologic Cancers	752
Ethical Consideration of Nutritional Support in Terminally Ill Patients	753
28. Basic Surgical Procedures in Gynaecologic Oncology	757
Urethral Catheterization	758
Pleurocentesis	758
Characteristics of Normal Pleural Fluid	759
Causes of Pleural Effusion	759
Symptoms	759
Purpose of Pleurocentesis	759
Contraindications	760
Techniques of Pleurocentesis	760
Potential Complications of Pleurocentesis	761
Chest Tube Insertion	761
Indications	761
Contraindications	761
Equipment	762
Techniques of Chest Tube Insertion	762
Complications of Chest Tube Insertion	763
Pleurodesis	764
Potential Risks of Pleurodesis	765
Abdominal Paracentesis for Ascites	765
Causes of Ascites	765
Contraindications of Paracentesis	766
Techniques of Abdominal Paracentesis	766
Additional Facts	767

Potential Complications of Paracentesis	768
Bladder Retraining and Care of Suprapubic Urinary Catheter	768
Bladder Retraining (Instruction to Patient)	769
Care of Suprapubic Catheter (Instruction to Patient)	769
Chemoport	771
Indications for Use of Chemoport	772
Contraindications	772
Possible Complications	772
Implantation Instructions	772
Accessing Implanted Port	774
29. Laparoscopic and Robotic Surgery in Gynaecologic Oncology	775
Introduction	776
Endometrial Cancer	776
Ovarian Cancer	777
Role of Laparoscopy in the Evaluation of Adnexal Mass	777
Role of Laparoscopy in the Staging and Re-Staging	778
Role of Laparoscopy in Advanced Ovarian Cancer	778
Cervical Cancer	779
Primary Surgical Treatment for Early-Stage Disease	779
Locally Advanced Cervical Cancer	779
Radical Trachelectomy with Laparoscopic Lymphadenectomy	780
Other Roles of Laparoscopy in Cervical Cancer	780
Robotic Surgery	780
Complications of Laparoscopy	782
Key Factors Related to Complications Laparoscopy	782
Vascular Injuries	783
Gastrointestinal Injuries	783
Urinary Injuries	784
Incisional Hernias	784

Port-Site Metastases	784
Gas Embolism	785
<i>Index</i>	789

Preface

Gynaecologic oncology is a very challenging field and an important component of gynaecology and oncology. It is one of the most important subjects in gynaecology. The management of patients with gynaecological cancers is complex, as the impact of the outcome of such cancers can be critical. Gynaecologic oncology is always perceived as the most difficult subject in obstetrics and gynaecology. However, this handbook will prove it otherwise. This handbook of gynaecologic oncology is a new addition to the current academic tomes and covers the essential breadth of knowledge ranging from the basics of carcinogenesis to the latest advances in the prevention and management of all gynaecological cancers, including breast cancer. It aims to provide readers with the information and data in a systematic and easy-to-understand format with numerous illustrations and images. It is designed to be handy and compact but with the content equivalent to that of a standard textbook. The book also introduces the readers to the new FIGO staging system, including FIGO staging 2014 for ovarian and fallopian tube carcinoma. It will serve as a useful reference for everyone in the medical field, including researchers, clinicians, house officers, pharmacists, doctors, specialists, postgraduate students, fellows and sub-specialty trainees in gynaecologic, radiation and medical oncology and lecturers in universities.

Rushdan Noor
Eng Hseon Tay
Jeffrey Low

